Does Eliquis Cause Low Platelet Count?
Apixaban (Eliquis) does not typically cause thrombocytopenia through its mechanism of action, but rare cases have been reported in clinical practice. 1
Mechanism and Why It Shouldn't Cause Thrombocytopenia
Apixaban works as a direct factor Xa inhibitor that blocks the coagulation cascade without affecting platelet production or function. 1 Unlike heparin-based anticoagulants, apixaban does not interact with platelet factor 4 (PF4) or cause immune-mediated platelet destruction. 1 Studies examining heparin-induced thrombocytopenia (HIT) have demonstrated that apixaban has no effect on the interactions between PF4 or PF4/heparin complexes and platelets. 1
Clinical Trial and FDA Data
In major clinical trials involving orthopedic surgery patients, thrombocytopenia (including platelet count decreases) occurred at a frequency of ≥0.1% but <1% in apixaban-treated patients. 2 The FDA drug label lists thrombocytopenia as a less common adverse reaction in the blood and lymphatic system disorders category. 2
In the AMPLIFY and AMPLIFY-EXT studies evaluating apixaban for DVT/PE treatment, thrombocytopenia was not listed among the common adverse reactions (≥1%). 2
Rare Case Reports vs. Clinical Use
Despite the mechanistic evidence suggesting apixaban should not cause thrombocytopenia, isolated case reports have documented this occurrence. 3, 4 One 2017 case report described apixaban-induced thrombocytopenia as "an uncommon, but life-threatening side effect." 3 A 2019 case report similarly documented thrombocytopenia as "a possible side effect of apixaban" that should be monitored closely. 4
Paradoxical Use in HIT Management
Apixaban is actually considered an acceptable treatment option for heparin-induced thrombocytopenia (HIT), which highlights that it does not cause the same immune-mediated platelet destruction as heparin. 1 The American Society of Hematology (ASH) 2018 guidelines list apixaban as an acceptable non-heparin anticoagulant option for HIT management, with a recommended dose of 10 mg twice daily. 1
Multiple studies have demonstrated that apixaban can be safely used in HIT patients, with platelet counts normalizing after switching from heparin to apixaban. 5, 6, 7 In one pilot study of 30 patients with suspected HIT, platelet counts normalized in all patients after starting apixaban therapy. 5
Clinical Approach When Thrombocytopenia Occurs
When thrombocytopenia develops in a patient taking apixaban, investigate alternative causes rather than automatically attributing it to the medication. 1 Look for:
- Concurrent medications that affect platelet counts
- Underlying hematologic disorders
- Infection or sepsis
- Liver disease or cirrhosis 8
- Malignancy 9
- Recent chemotherapy exposure 9
Important Caveats
Patients with baseline thrombocytopenia or platelet counts <50,000/mm³ were typically excluded from major clinical trials, so safety data in this population is limited. 1
In patients with cancer-associated thrombosis and thrombocytopenia, current guidelines recommend standard-dose anticoagulation with platelet counts >50,000/μL and no evidence of bleeding, with case-by-case decisions for platelet counts <50,000/μL. 9 The 2018 ISTH guidance suggests withholding anticoagulation in patients with platelet counts <25,000/μL who are at lower risk for recurrent VTE. 9